BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, June 19, 2026
Home » Topics » Infection » Coronavirus

Coronavirus
Coronavirus RSS Feed RSS

Regulatory actions for Nov. 4, 2021

Nov. 4, 2021
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Allena, Astrazeneca, BMS, Biontech, Daiichi, Inovio, Effrx, Enlivex, Epizyme, Innovent, Inovio, Kangtai, Lipocine, Macrogenics, Menarini, Merck, Merus, Minerva, Neurona, Novavax, Ocugen, OS, Pfizer, Rafael, Ridgeback, Transthera, Union, Y-mabs.
Read More

Other news to note for Nov. 4, 2021

Nov. 4, 2021
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: 2seventy, AC Immune, Affimed, Alterity, Amgen, Aptose, Ardelyx, Astrazeneca, Betterlife, Bluebird, Cassava, Cour, Epivax, Hanmi, Inspirna, Ironwood, Karolinska, Maruho, Omass, Oncternal, Orion, Phagelux, Recode, Soligenix, Tranquis, Umecrine Cognition, Uvax, Vyne, Xoma.
Read More

Regulatory actions for Nov. 3, 2021

Nov. 3, 2021
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Insightec, Lumos Diagnostics, Mim Software.
Read More

Other news to note for Nov. 3, 2021

Nov. 3, 2021
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aditxt, Betternight, Clario, Cytek Biosciences, Exact Sciences, Heartflow, Innovia, Molex, Nanostring Technologies, Peerbridge Health, Phillips-Medize, Sleep Data Services.
Read More

Covaxin gets nod from WHO as CDC endorses Pfizer’s COVID-19 vaccine for children

Nov. 3, 2021
By Lee Landenberger
A few hours after the U.S. CDC Advisory Committee on Immunization Practices’ Nov. 2 recommendation to allow children ages 5 through 11 to be administered Pfizer Inc. and Biontech SE’s COVID-19 vaccine, Comirnaty (tozinameran), the agency’s director, Rochelle Walensky, endorsed the recommendation. The recommendation came as the World Health Organization (WHO) expanded the COVID-19 vaccines it recommends in the fight against the pandemic by endorsing Bharat Biotech International Ltd.’s Covaxin.
Read More
Financial chart

Biopharma stocks boosted by pandemic, pressured by changing landscape

Nov. 3, 2021
By Karen Carey
Although the BioWorld Biopharmaceutical Index has recovered slightly within the last month, it is showing only a small gain since the start of the year. Up by 2.82%, it is somewhat in line with the Nasdaq Biotechnology Index gain of 4.83%, but significantly beneath the broader markets. The Dow Jones Industrial Average, for example, was up by 17.03% at the end of October.
Read More
Bamlanivimab and etesevimab

Lilly pulls EU filing for COVID-19 antibody cocktail as authorities back rivals, US places $1.29B order

Nov. 3, 2021
By Richard Staines
Eli Lilly and Co. has withdrawn a filing for its COVID-19 antibody cocktail in Europe after health authorities backed rivals – the day after a $1.29 billion purchase of the same medicines from the U.S. government. Indianapolis-based Lilly began filing data from the combination of bamlanivimab and etesevimab in March to enable a fast authorization by the European Medicines Agency.
Read More

Other news to note for Nov. 3, 2021

Nov. 3, 2021
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Autobahn, Biomunex, Cytovant, Defence, Eisbach, Flagship Pioneering, Gb, Medigene, Pharmather, Reithera, Resverlogix, Revive, Roivant, Tessera.
Read More

In the clinic for Nov. 3, 2021

Nov. 3, 2021
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Bridge, Cytodyn, Innovation, Ionis, Kintor, Macrogenics, Minoryx, Mycovia, Oncolytic, Phasebio, Pieris, RDIF, Rigel, Sage, Sumitomo, Xencor.
Read More
Man looking at Physiq smartwatch on wrist

Physiq and Purdue develop infection-detection watch

Nov. 2, 2021
By Annette Boyle
As a counterpoint to the raft of wellness-promoting smartwatches, Purdue University and Physiq Inc. have developed a smartwatch algorithm that flags illness. A year after launching their co-development program, the two organizations reported they have created an algorithm designed for smartwatches that enables detection of early signs of infection. The algorithm is already in use in a number of Physiq’s customers’ applications, Physiq Chief Scientific Officer Stephan Wegerich told BioWorld.
Read More
Previous 1 2 … 168 169 170 171 172 173 174 175 176 … 552 553 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 18, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 16, 2026
  • Brain with puzzle piece removed

    Gene replacement rescues autism-related phenotypes in mice

    BioWorld Science
    Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
  • Red blood cells, DNA

    For clonal hematopoiesis, epigenetics can be in driver’s seat

    BioWorld Science
    Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
  • Illustration of amyloid plaques in Alzheimer's disease

    Elixiron’s enrupatinib shows upbeat interim phase II AD results

    BioWorld
    Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing